BridgeBio Pharma Inc

BBIONASDAQ · USD
76.03USD0.00 (-2.75%)
239

BridgeBio Pharma Inc (BBIO) Covered Calls

BridgeBio Pharma Inc trades in the Biotechnology industry with an IV Rank of 26.59%, low versus the past year. BBIO's highest covered call setup is the $90.00 strike expiring Dec 18, 2026, sorted by theoretical annualized return. It's 18.37% out of the money with 28 days to expiration, a 18.64% return until expiration, and a 242.95% theoretical annualized return. Across the setups shown, annualized returns run from 89.87% to 242.95% at strikes between $80.00 and $110.00, with 28 to 182 days to expiration, as of Nov 20, 2026.

Read more

Running BBIO covered calls helps you generate income from BridgeBio Pharma Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best BBIO covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If BBIO stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling BBIO covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given BBIO covered call is worth writing.

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.

2026-12-182890.0018.370.201.001417.0018.64242.95-0.26+0.12470.80
2026-12-182885.0011.801.001.70997.0013.11170.94-1.32+0.24900.70
2026-12-182882.508.510.903.60737.009.69126.36-1.18+0.33722.70
2027-03-19119105.0038.100.403.402937.0038.63118.49-0.53+0.18103.00
2026-12-182880.005.222.004.20597.007.85102.36-2.63+0.411862.20
2027-02-199195.0024.950.104.001907.0025.08100.60-0.13+0.221313.90
2027-01-155687.5015.090.053.901152.0015.1598.76-0.07+0.262103.85
2027-03-19119100.0031.530.054.002402.0031.5996.90-0.07+0.2033.95
2027-02-199192.5021.660.604.401707.0022.4590.05-0.79+0.2623.80
2027-05-21182110.0044.680.103.203407.0044.8189.87-0.13+0.16123.10

As of Nov 20, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank26.59% Low
  • Market cap (M$)14,811
  • 52 weeks high-18.61%
  • 52 weeks low21.65%
  • Analyst recommendationStrong Buy
    1.35
  • Target price$109.72
    44.31% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-10-29
  • P/E—
  • Future P/E—
  • EPS (ttm)-3.04
  • EPS growth next 5 years—

As of Nov 20, 2026